BRPI0913045A2 - vetor de expressão codificador de alfa-vírus replicase e uso do mesmo como adjuvante imunológico - Google Patents

vetor de expressão codificador de alfa-vírus replicase e uso do mesmo como adjuvante imunológico

Info

Publication number
BRPI0913045A2
BRPI0913045A2 BRPI0913045A BRPI0913045A BRPI0913045A2 BR PI0913045 A2 BRPI0913045 A2 BR PI0913045A2 BR PI0913045 A BRPI0913045 A BR PI0913045A BR PI0913045 A BRPI0913045 A BR PI0913045A BR PI0913045 A2 BRPI0913045 A2 BR PI0913045A2
Authority
BR
Brazil
Prior art keywords
alpha
expression vector
immune adjuvant
coding expression
virus replicase
Prior art date
Application number
BRPI0913045A
Other languages
English (en)
Portuguese (pt)
Inventor
Männik Andres
Kiiver Kaja
Kaldma Katrin
Ustav Mart
Sikut Rein
Mölder Tarmo
Toots Urve
Original Assignee
Fit Biotech Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fit Biotech Oy filed Critical Fit Biotech Oy
Publication of BRPI0913045A2 publication Critical patent/BRPI0913045A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/127—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0913045A 2008-05-23 2009-05-22 vetor de expressão codificador de alfa-vírus replicase e uso do mesmo como adjuvante imunológico BRPI0913045A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7189808P 2008-05-23 2008-05-23
PCT/EP2009/056240 WO2009141434A1 (en) 2008-05-23 2009-05-22 Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant

Publications (1)

Publication Number Publication Date
BRPI0913045A2 true BRPI0913045A2 (pt) 2017-05-23

Family

ID=40910781

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0913045A BRPI0913045A2 (pt) 2008-05-23 2009-05-22 vetor de expressão codificador de alfa-vírus replicase e uso do mesmo como adjuvante imunológico

Country Status (15)

Country Link
US (1) US9474800B2 (enExample)
EP (1) EP2296702A1 (enExample)
JP (1) JP5663474B2 (enExample)
KR (1) KR20110044836A (enExample)
CN (1) CN102083463B (enExample)
AU (1) AU2009248735B2 (enExample)
BR (1) BRPI0913045A2 (enExample)
CA (1) CA2724570A1 (enExample)
IL (1) IL209077A0 (enExample)
MX (1) MX2010012587A (enExample)
NZ (1) NZ589495A (enExample)
RU (1) RU2010152562A (enExample)
SG (1) SG191600A1 (enExample)
WO (1) WO2009141434A1 (enExample)
ZA (1) ZA201007880B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201220119D0 (en) * 2012-11-08 2012-12-26 Univ Cork Vector
CN111304201B (zh) * 2020-02-21 2022-10-21 华南农业大学 一种降低乙型脑炎脑病毒感染的siRNA及其应用
JP2023517644A (ja) * 2020-03-09 2023-04-26 アークトゥラス・セラピューティクス・インコーポレイテッド コロナウイルスワクチン組成物及び方法
US12178921B2 (en) 2020-08-14 2024-12-31 Arcturus Therapeutics, Inc. Method of lyophilizing lipid nanoparticles
CN113846113B (zh) * 2021-09-09 2022-09-13 臻赫医药(杭州)有限公司 一种有限自我复制mRNA分子系统、制备方法及应用
JP2025504364A (ja) * 2022-01-08 2025-02-12 カロジェン コーポレイション 慢性ｂ型肝炎感染症を処置または防止するための複数抗原治療ワクチン
KR20240049429A (ko) 2022-10-08 2024-04-16 최주언 황금비율 계량컵

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5684136A (en) * 1992-05-18 1997-11-04 Genentech, Inc. Chimeric hepatocyte growth factor (HGF) ligand variants
SE9401091D0 (sv) * 1994-03-31 1994-03-31 Bioption Ab Alphavirus cDNA vectors
SE9401709D0 (sv) * 1994-05-18 1994-05-18 Mathilda Sjoeberg Improved alphavirus vectors for expression of heterologous DNA
JP2002521461A (ja) * 1998-07-29 2002-07-16 インビトロゲン・コーポレーション Ｒｎａウイルスを用いる組換えタンパク質の調節発現
EP1226238A2 (en) * 1999-10-27 2002-07-31 Cytos Biotechnology AG Method for creating divergent populations of nucleic acid molecules and proteins
WO2002057316A1 (en) * 2000-12-28 2002-07-25 Kirin Beer Kabushiki Kaisha Novel monoclonal antibody
FI116851B (fi) * 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
US20060251620A1 (en) * 2002-08-22 2006-11-09 Lidia Ivanova Inducible alphaviral/orip based gene expression system
ES2222095B1 (es) * 2003-07-02 2005-11-16 Instituto Nacional De Investigacion Y Tecnologia Agraria Y Alimentaria Inia Virus adn recombinantes que comprenden un adn complementario de un replicon de un virus arn y sus aplicaciones.
AU2005327198B2 (en) * 2004-07-09 2011-03-31 University Of North Carolina At Chapel Hill Viral adjuvants
AU2007342333B2 (en) * 2006-09-12 2013-02-28 Alphavax, Inc. Alphavirus replicon particles encoding IL- 12 as immunological adjuvants
WO2008065225A2 (es) * 2006-11-28 2008-06-05 Proyecto De Biomedicina Cima, S.L. Vector viral y sus aplicaciones
WO2008119827A1 (en) * 2007-04-02 2008-10-09 Fit Biotech Oy Transreplicase constructs

Also Published As

Publication number Publication date
JP2011523642A (ja) 2011-08-18
US9474800B2 (en) 2016-10-25
JP5663474B2 (ja) 2015-02-04
AU2009248735B2 (en) 2015-08-20
MX2010012587A (es) 2011-05-25
CN102083463A (zh) 2011-06-01
SG191600A1 (en) 2013-07-31
EP2296702A1 (en) 2011-03-23
CA2724570A1 (en) 2009-11-26
NZ589495A (en) 2012-06-29
US20110171255A1 (en) 2011-07-14
AU2009248735A1 (en) 2009-11-26
RU2010152562A (ru) 2012-06-27
ZA201007880B (en) 2012-02-29
WO2009141434A1 (en) 2009-11-26
KR20110044836A (ko) 2011-05-02
IL209077A0 (en) 2011-01-31
WO2009141434A4 (en) 2010-01-14
CN102083463B (zh) 2017-04-05

Similar Documents

Publication Publication Date Title
IL294454B2 (en) Context initialization in entropy coding
ES2790625T8 (es) Polisiloxanos con grupos con contenido en nitrógeno
IL250764A0 (en) Anti-mesothelin antibodies and immunoconjugates
BRPI1006030A2 (pt) reclinador de banco, e, banco
BR112013012305A2 (pt) preparações contendo polissiloxanos com grupos nitrogenados
BR112014011261A2 (pt) composição de borracha, e pneumático
IL221704A (en) Vein expansion system
BR112013010725A2 (pt) método, e, composição
EP2502951A4 (en) organopolysiloxane
BR112013011929A2 (pt) disjuntor com escape controlado
HUE031343T2 (hu) Immunitásindukáló ágens
DK2651436T3 (da) Mycobakterie antigen sammensætning.
EP2595881A4 (en) TAIL BEAM IN THE FORM OF AERODYNAMIC PROFILE
BRPI1009405A2 (pt) vedação mecânica, e, bomba
DK2568854T3 (da) Sædeindretning
IT1403806B1 (it) Composizione cosmetica.
LT2552484T (lt) Būdai ir kompozicijos, skirti paratiroidų lygiams sumažinti
EP2578812A4 (en) STEAM VALVE
BR112013009525A2 (pt) unidade de descompressão
DK2536914T3 (da) Ventilindretning
IL209077A0 (en) Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant
BRPI1007584A2 (pt) vacina de sarampo-malária combinada, vetor de vírus de vacina de sarampo, hospedeiro e composição de vacina de sarampo-malária combinada
FR2962511B1 (fr) Vanne perfectionnee, et application
EP2558705A4 (en) SLIDING VALVE ASSEMBLY
KR101292608B9 (ko) 클램프

Legal Events

Date Code Title Description
B08E Application fees: payment of additional fee required [chapter 8.5 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]